Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1675-1684

  Cheng, Qingbao ^a   Yi, Bin ^a   Wang, Aihua ^a   Jiang, Xiaoqing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cell; Epithelial mesenchymal transition; miRNA; Tumor microenvironment

Indexed keywords

MICRORNA; MICRORNA 128; MICRORNA 145; MICRORNA 23A; MICRORNA 490 3P; RNA; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER STEM CELL; CARCINOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HYPOXIA; LUNG CANCER; MOLECULAR PATHOLOGY; NONHUMAN; PROSTATE CANCER; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84888153809     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S52730     Document Type: Review

References (115)

1. Lee RC, Feinbaum RL, Ambros V. The C elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843-854.
2. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol. 2012;22:396-403.
3. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol. 2011;223:147-161.
4. Garg M. MicroRNAs, stem cells and cancer stem cells. World J Stem Cells. 2012;4:62-70.
5. Li Y, Vecchiarelli-Federico LM, Li YJ, etal. The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. Blood. 2012;119:4486-4498.
6. Northcott PA, Fernandez-L A, Hagan JP, etal. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res. 2009;69:3249-3255.
7. Taguchi A, Yanagisawa K, Tanaka M, etal. Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92microRNA cluster. Cancer Res. 2008;68:5540-5545.
8. Chen HC, Chen GH, Chen YH, etal. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 2009;100:1002-1011.
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857-866.
10. Yu F, Yao H, Zhu P, etal. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131:1109-1123.
11. Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010;29:4194-4204.
12. Shimono Y, Zabala M, Cho RW, etal. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138: 592-603.
13. Okuda H, Xing F, Pandey PR, etal. miR-7suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res. 2013;73:1434-1444.
14. Liu S, Patel SH, Ginestier C, etal. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet. 2012;8(6):e1002751.
15. Yu XY, Zhang Z, Liu J, Zhan B, Kong CZ. MicroRNA-141 is downregulated in human renal cell carcinoma and regulates cell survival by targeting CDC25B. Onco Targets Ther. 2013;6:349-354.
16. Hudson RS, Yi M, Esposito D, etal. MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene. 2013;32(35): 4139-4147.
17. Fan X, Chen X, Deng W, Zhong G, Cai Q, Lin T. Up-regulated microRNA-143in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression. BMC Cancer. 2013;13:61.
18. Huang S, Guo W, Tang Y, Ren D, Zou X, Peng X. miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep. 2012;28:1831-1837.
19. Hsieh IS, Chang KC, Tsai YT, etal. MicroRNA-320suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis. 2013;34: 530-538.
20. Saini S, Majid S, Shahryari V, etal. miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res. 2012;72:3618-3630.
21. Ryu S, McDonnell K, Choi H, etal. Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. Cancer Cell. 2013;23:63-76.
22. Gal H, Pandi G, Kanner AA, etal. MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem Biophys Res Commun. 2008;376:86-90.
23. Guessous F, Alvarado-Velez M, Marcinkiewicz L, etal. Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol. 2013;112: 153-163.
24. Wu N, Xiao L, Zhao X, etal. miR-125b regulates the proliferation of glioblastoma stem cells by targeting E2F2. FEBS Lett. 2012;586: 3831-3839.
25. Ying Z, Li Y, Wu J, etal. Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. Cancer Res. 2013;73:990-999.
26. Chan XH, Nama S, Gopal F, etal. Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138in malignant gliomas. Cell Rep. 2012;2:591-602.
27. Liu C, Kelnar K, Liu B, etal. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17:211-215.
28. Ji Q, Hao X, Zhang M, etal. MicroRNA miR-34inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4:e6816.
29. Sun L, Wu Z, Shao Y, etal. MicroRNA-34a suppresses cell proliferation and induces apoptosis in U87glioma stem cells. Technol Cancer Res Treat. 2012;11:483-490.
30. Yang S, Li Y, Gao J, etal. MicroRNA-34suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene. 2013;32(36):4294-4303.
31. Pagliuca A, Valvo C, Fabrizi E, etal. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. Epub Novmber 5, 2012.
32. De Vito C, Riggi N, Cornaz S, etal. A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer Cell. 2012;21: 807-821.
33. Tang M, Lin L, Cai H, Tang J, Zhou Z. MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patients suffering osteosarcoma. Onco Targets Ther. 2013;6: 833-838.
34. Xia H, Cheung WK, Ng SS, etal. Loss of brain-enriched miR-124microRNA enhances stem-like traits and invasiveness of glioma cells. J Biol Chem. 2012;287:9962-9971.
35. Wang P, Chen L, Zhang J, etal. Methylation-mediated silencing of the miR-124genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene. Epub January 32, 2013.
36. Yu PN, Yan MD, Lai HC, etal. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer. Epub August 1, 2013.
37. Cittelly DM, Finlay-Schultz J, Howe EN, etal. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene. 2013;32(20):2555-2564.
38. Wang H, Garzon R, Sun H, etal. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 2008;14:369-381.
39. Zhang X, Zhao X, Fiskus W, etal. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell. 2012;22:506-523.
40. Zhang J, Luo N, Luo Y, Peng Z, Zhang T, Li S. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol. 2012;40:747-756.
41. Jin H, Lv S, Yang J, etal. Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells. PLoS One. 2011;6:e21307.
42. Meng F, Glaser SS, Francis H, etal. Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med. 2012;16: 160-173.
43. Xia H, Ooi LL, Hui KM. MiR-214 targets beta-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One. 2012;7:e44206.
44. Xu CX, Xu M, Tan L, etal. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem. 2012;287: 34970-34978.
45. Shi L, Zhang S, Feng K, etal. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 2012;40:119-129.
46. Zhang S, Wan Y, Pan T, etal. MicroRNA-21inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. J Mol Neurosci. 2012;47:346-356.
47. Han M, Liu M, Wang Y, etal. Antagonism of miR-21reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2inactivation by targeting PTEN. PLoS One. 2012;7:e39520.
48. Liu X, Sempere LF, Galimberti F, etal. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res. 2009;15:1177-1183.
49. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y. Decreased expression of microRNA-143 and-145in human gastric cancers. Oncology. 2009;77:12-21.
50. Deng H, Guo Y, Song H, etal. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 2013;518(2):351-359.
51. La Rocca G, Badin M, Shi B, etal. Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway. J Cell Physiol. 2009;220:485-491.
52. Dyrskjot L, Ostenfeld MS, Bramsen JB, etal. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69:4851-4860.
53. Tong AW, Fulgham P, Jay C, etal. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 2009;16:206-216.
54. Wang S, Bian C, Yang Z, etal. miR-145inhibits breast cancer cell growth through RTKN. Int J Oncol. 2009;34:1461-1466.
55. Yang YP, Chien Y, Chiou GY, etal. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials. 2012;33:1462-1476.
56. Dynoodt P, Speeckaert R, De Wever O, etal. miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. Int J Oncol. 2013;42(4):1443-1451.
57. Katsushima K, Shinjo K, Natsume A, etal. Contribution of microRNA-1275 to Claudin11 protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells. J Biol Chem. 2012;287:27396-27406.
58. Liu S, Tetzlaff MT, Cui R, Xu X. miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am J Pathol. 2012;181:1823-1835.
59. Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW, Mahato RI. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PLoS One. 2012;7:e40021.
60. Lo WL, Yu CC, Chiou GY, etal. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J Pathol. 2011;223:482-495.
61. Zhu Y, Yu F, Jiao Y, etal. Reduced miR-128in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res. 2011;17:7105-7115.
62. Qian P, Banerjee A, Wu ZS, etal. Loss of SNAIL regulated miR-128-2 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells. Cancer Res. 2012;72:6036-6050.
63. Godlewski J, Nowicki MO, Bronisz A, etal. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128inhibits glioma proliferation and self-renewal. Cancer Res. 2008;68:9125-9130.
64. Gregory PA, Bert AG, Paterson EL, etal. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593-601.
65. Chen Y, Sun Y, Chen L, etal. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep. 2013;7(5):1579-1584.
66. Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia. 2013;15: 180-191.
67. Cong N, Du P, Zhang A, etal. Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/beta-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2in gastric adenocarcinoma. Oncol Rep. 2013;29:1579-1587.
68. Zhang LY, Liu M, Li X, Tang H. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem. 2013;288:4035-4047.
69. He Y, Cui Y, Wang W, etal. Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia. 2011;13:841-853.
70. Xu X, Fan Z, Kang L, etal. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest. 2013;123(2):630-645.
71. Yan Y, Luo YC, Wan HY, etal. MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelial-mesenchymal transition and adhesion in hepatoma cells. Hepatology. 2013;57:667-677.
72. Wong CC, Wong CM, Tung EK, etal. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011;140: 322-331.
73. Jiang J, Gusev Y, Aderca I, etal. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008;14:419-427.
74. Wang Y, Lee AT, Ma JZ, etal. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem. 2008;283:13205-13215.
75. Li B, Han Q, Zhu Y, Yu Y, Wang J, Jiang X. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J. 2012;279:2393-2398.
76. Papadimitriou E, Vasilaki E, Vorvis C, etal. Differential regulation of the two RhoA-specific GEF isoforms Net1/Net1A by TGF-beta and miR-24: role in epithelial-to-mesenchymal transition. Oncogene. 2012;31:2862-2875.
77. Ma L, Young J, Prabhala H, etal. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12:247-256.
78. Guo L, Chen C, Shi M, etal. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene. Epub January 14, 2013.
79. Smith AL, Iwanaga R, Drasin DJ, etal. The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1in human breast cancer. Oncogene. 2012;31:5162-5171.
80. Liang YJ, Wang QY, Zhou CX, etal. MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis. 2013;34:713-722.
81. Hunt S, Jones AV, Hinsley EE, Whawell SA, Lambert DW. MicroRNA-124suppresses oral squamous cell carcinoma motility by targeting ITGB1. FEBS Lett. 2011;585:187-192.
82. Zheng F, Liao YJ, Cai MY, etal. The putative tumour suppressor microRNA-124modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012;61:278-289.
83. Ward A, Balwierz A, Zhang JD, etal. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. 2013;32:1173-1182.
84. Cao M, Seike M, Soeno C, etal. MiR-23a regulates TGF-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol. 2012;41:869-875.
85. Xu Q, Sun Q, Zhang J, Yu J, Chen W, Zhang Z. Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer. Carcinogenesis. 2013;34:539-549.
86. Hamada S, Satoh K, Miura S, etal. miR-197induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol. 2013;228:1255-1263.
87. Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013;58:629-641.
88. Oishi N, Kumar MR, Roessler S, etal. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology. 2012;56:1792-1803.
89. Puhr M, Hoefer J, Schafer G, etal. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 2012;181: 2188-2201.
90. Tucci P, Agostini M, Grespi F, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A. 2012;109:15312-15317.
91. Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther. 2012;11:1166-1173.
92. Liu YN, Yin JJ, Abou-Kheir W, etal. MiR-1 and miR-200inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene. 2013;32:296-306.
93. Toyota M, Suzuki H, Sasaki Y, etal. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68: 4123-4132.
94. Vogt M, Munding J, Grüner M, etal. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 2011;458:313-322.
95. Corney DC, Hwang CI, Matoso A, etal. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010;16: 1119-1128.
96. Yu F, Jiao Y, Zhu Y, etal. MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells. J Biol Chem. 2012;287: 465-473.
97. Siemens H, Jackstadt R, Hunten S, etal. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle. 2011;10:4256-4271.
98. Yang D, Sun Y, Hu L, etal. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23:186-199.
99. Wentz-Hunter KK, Potashkin JA. The role of miRNAs as key regulators in the neoplastic microenvironment. Mol Biol Int. 2011;2011:839872.
100. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol. 2013;15: 201-213.
101. Sengupta S, den Boon JA, Chen IH, etal. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A. 2008;105:5874-5878.
102. Bronisz A, Godlewski J, Wallace JA, etal. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol. 2012;14:159-167.
103. Schliekelman MJ, Gibbons DL, Faca VM, etal. Targets of the tumor suppressor miR-200in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res. 2011;71:7670-7682.
104. Musumeci M, Coppola V, Addario A, etal. Control of tumor and microenvironment cross-talk by miR-15a and miR-16in prostate cancer. Oncogene. 2011;30:4231-4242.
105. Wurdinger T, Tannous BA, Saydam O, etal. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell. 2008;14:382-393.
106. Yang P, Li QJ, Feng Y, etal. TGF-beta-miR-34a-CCL22signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22:291-303.
107. Dudda JC, Salaun B, Ji Y, etal. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity. 2013;38:742-753.
108. He S, Chu J, Wu LC, etal. MicroRNAs activate natural killer cells through Toll-like receptor signaling. Blood. 2013;121:4663-4671.
109. Min S, Liang X, Zhang M, etal. Multiple tumor-associated microRNAs modulate the survival and longevity of dendritic cells by targeting YWHAZ and Bcl2signaling pathways. J Immunol. 2013;190: 2437-2446.
110. Yang J, Zhang Z, Chen C, etal. MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene. Oncogene. Epub July 8, 2013.
111. Hwang-Verslues WW, Chang PH, Wei PC, etal. miR-495 is upregulated by E12/E47in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene. 2011;30:2463-2474.
112. Mace TA, Collins AL, Wojcik SE, Croce CM, Lesinski GB, Bloomston M. Hypoxia induces the overexpression of microRNA-21in pancreatic cancer cells. J Surg Res. 2013;184(2):855-860.
113. Yoshioka Y, Kosaka N, Ochiya T, Kato T. Micromanaging Iron Homeostasis: hypoxia-inducible micro-RNA-210suppresses iron homeostasis-related proteins. J Biol Chem. 2012;287:34110-34119.
114. Shen J, Xia W, Khotskaya YB, etal. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature. 2013;497:383-387.
115. Chen Z, Lai TC, Jan YH, etal. Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis. J Clin Invest. 2013;123: 1057-1067.